Abbott Laboratories vs Rent the Runway Inc — how do they compare? Abbott Laboratories trades at $112.96 (market cap $191.92B), while Rent the Runway Inc trades at $3.51 (market cap $119.45M). The key difference: Abbott Laboratories is far larger — about 1606.7× Rent the Runway Inc's market cap, and Abbott Laboratories pays a 2.27% dividend while Rent the Runway Inc pays none. Which is the better fit depends on your goals.
| ABT | RENT | |
|---|---|---|
Market Cap | $191.92B | $119.45M |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $9.39 |
52-Week Low | $82.57 | $3.01 |
Enterprise Value | $218.92B | $279.55M |
Dividend Yield | 2.27% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.02% with strong analyst support (75.6% buy ratings) and a $120.70 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026. Fundamentals remain solid with $44.33B revenue, 11.65% net margin, and improving cash flow trends. Recent CE Mark approval for Libre Duo glucose-ketone sensors highlights innovation momentum.
ABT presents a compelling investment case with strong fundamentals, positive analyst sentiment, and innovative product pipeline. Key risks include competitive pressures in medical devices and potential macroeconomic headwinds affecting healthcare spending. The stock's current valuation at 35.15 P/E appears reasonable given growth prospects and dividend stability.
Rent the Runway (RENT) trades at $3.60, down 1.1% on the day. The stock shows a bullish technical signal with positive moving averages, while fundamentals reveal a mixed picture: revenue grew to $306.20M in 2025 (company filing, 2025), but net losses persist at -$69.90M. Recent leadership changes, with Teri Bariquit appointed interim CEO (GlobeNewsWire, 2026-05-13), add a layer of transition. The company maintains a high gross margin of 73.81%, yet negative shareholder equity of -$182.50M signals significant financial leverage.
The outlook is cautiously optimistic. A low P/S ratio of 0.2 suggests potential undervaluation if the company can achieve projected profitability in 2026. However, high debt levels, consecutive annual net losses, and execution risks under new leadership pose substantial threats to shareholder value. Analyst sentiment is divided, with a 'Hold' bias reflecting this uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →